Therapeutic Potential Of Human Adipose Tissue-derived Multi-lineage Progenitor Cells In Non-alcoholic Fatty Liver Disease | 49577
Journal of Biotechnology & Biomaterials
Like us on:
Our Group organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.
Nonalcoholic fatty liver disease (NAFLD) is an increasing cause of chronic liver disease and broadly defined by the presence
of steatosis with inflammation and progressive fibrosis. Recently, we have reported the therapeutic potential of adipose
tissue-derived multi-lineage progenitor cells (ADMPCs) in liver fibrosis using CCl4-induce chronic mice model. These
findings lead us to plan next study, whose aim was to assess the effectiveness of ADMPCs in improving NAFLD. ADMPCs were
isolated from inguinal adipose tissues of C57 BL/6 mice and expanded. NAFLD model was induced by a single subcutaneous
injection of 200 μg STZ 2 day-after birth followed by feeding a high fat diet beginning at 4 weeks of age. After randomization of
animals, the NAFLD mice received ADMPCs or placebo control via tail vein injection at an age of 6 weeks and were applied for
histological and blood examination at an age of 9 weeks. NAFLD model mice with ADMPCs injection exhibited a significant
reduction in liver fibrosis and inflammation areas as evidenced by Sirius red staining. Moreover, blood examination showed
that plasma adiponectin levels in ADMPCs-treated NAFLD model mice were higher than those in placebo controls. In vitro
production of anti-inflammatory cytokines, fibrinolytic enzymes and hepato-protective cytokines examined by ELISA were
higher than those of and BM-MSCs, suggesting the mode of action of ADMPCs. These results showed the mode of action and
proof of concept of systemic injection of ADMPCs in NAFLD, which is a promising therapeutic intervention for the treatment
of patients with NAFLD.
Hanayuki Okura has completed her PhD degree from Osaka University, Graduate School of Medicine. She is the Deputy Director of Platform of Therapeutics for Rare Diseases, National Institute of Biomedical Innovation, National Institute of Biomedical Innovation, Health and Nutrition, Japan.